Are you Dr. Cannistra?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 77 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Beth Israel Deaconess Medical Center
Boston, MA 02215Phone+1 617-667-4283
Summary
- Dr. Stephen Cannistra, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Beth Israel Deaconess Medical Center and is a Professor of Medicine at Beth Israel Deaconess Medical Center.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1982 - 1984
Johns Hopkins UniversityResidency, Internal Medicine, 1979 - 1981
The Warren Alpert Medical School of Brown UniversityClass of 1979
Certifications & Licensure
MA State Medical License 1982 - 2021
Clinical Trials
- Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer Start of enrollment: 1999 Jul 01
- Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors Start of enrollment: 1999 Jul 01
- Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2002 May 01
Publications & Presentations
PubMed
- Flashback Foreword: Carboplatin Dosage Based on Renal Function.Robert G Maki, Stephen A Cannistra
Journal of Clinical Oncology. 2023-10-01 - 17 citationsImmune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?Panagiotis A. Konstantinopoulos, Stephen A. Cannistra
Journal of Clinical Oncology. 2021-04-23 - 1 citationsThe End of a Fantastic Voyage.Stephen A. Cannistra
Journal of Clinical Oncology. 2021-04-20
Press Mentions
Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian CancerOctober 28th, 2019
Grant Support
- Cp-547,632 In Subjects With CancerNational Center For Research Resources2005
- Adhesion Protein And Ovarian Cancer ImplantationNational Cancer Institute1993–1996
- Role Of IA Antigens In Regulation Of Human MyelopoiesisNational Cancer Institute1985–1986
Professional Memberships
- Member
